74 filings
Page 2 of 4
8-K
dvb7m3wshmh
1 Sep 22
Departure of Directors or Certain Officers
4:03pm
EFFECT
o0g1z6mcxa4iw
30 Aug 22
Notice of effectiveness
12:15am
424B5
07ko mzmsrx6r0
29 Aug 22
Prospectus supplement for primary offering
4:46pm
CORRESP
vzvuxw
25 Aug 22
Correspondence with SEC
12:00am
UPLOAD
90yumehk2jfj5z
19 Aug 22
Letter from SEC
12:00am
8-K
l4mbgx0 qtxv
18 Aug 22
Other Events
5:29pm
S-3
l768 dp8wua3i5
18 Aug 22
Shelf registration
5:10pm
8-K
64ijngc54 9fpdlvmyw
12 Aug 22
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
4:18pm
8-K
lqm 92648ghheu2u5
13 Jun 22
Regulation FD Disclosure
6:07am
8-K
mh6wm5rdo ja0gy72
10 Jun 22
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
6:05am
8-K
nynxv9fvjufs78v2y
6 Jun 22
Submission of Matters to a Vote of Security Holders
8:19am
8-K
qi7m7ckdl1cwfo
12 May 22
Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates
4:28pm
8-K
e5p34g3s
12 May 22
Regulation FD Disclosure
10:39am
8-K
sx9mw yo0s
9 May 22
Regulation FD Disclosure
10:01am
8-K
lg9mbx3k
3 May 22
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
8:31am
DEFA14A
dqyfp0 lf24jedtz
19 Apr 22
Additional proxy soliciting materials
6:12am
DEF 14A
fjlxx4
19 Apr 22
Definitive proxy
6:07am
S-8
w5can5u1jtqhq4
24 Mar 22
Registration of securities for employees
5:01pm